[
  {
    "drug_name": "Darolutamide",
    "application_number": "213072",
    "application_type": "NDA",
    "approval_status": "approved",
    "deficiency_categories": ["oncology_specific"],
    "openfda_generic_name": "Darolutamide"
  },
  {
    "drug_name": "Sintilimab",
    "application_number": "761222",
    "application_type": "BLA",
    "approval_status": "unapproved",
    "deficiency_categories": ["oncology_specific", "clinical_trial_design"],
    "openfda_generic_name": "Sintilimab"
  },
  {
    "drug_name": "Retifanlimab",
    "application_number": "761155",
    "application_type": "BLA",
    "approval_status": "unapproved",
    "deficiency_categories": ["oncology_specific", "efficacy"],
    "openfda_generic_name": "Retifanlimab"
  },
  {
    "drug_name": "Granisetron",
    "application_number": "207987",
    "application_type": "NDA",
    "approval_status": "approved",
    "deficiency_categories": ["oncology_specific", "cmc_manufacturing"],
    "openfda_generic_name": "Granisetron"
  }
]
